OTCM
MAQAF
Market cap3.75bUSD
, Last price
Name
Atlas Arteria Group
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Atlas Arteria Limited specializes in the acquisition, development, and management of toll road assets. Among its key holdings is a 13.4% equity stake in Toll Road Investors Partnership II (TRIP II), the concessionaire responsible for the 22-kilometer Dulles Greenway toll road, situated in Virginia, United States. The company was established in 2009 and operates from its corporate headquarters in Melbourne, Australia. It formally rebranded from Macquarie Atlas Roads Limited to its current name, Atlas Arteria Limited, in May 2018.
Key people
Non-Executive Independent Chairman of the Board of ATLAX, Independent Non- Executive Director of ATLIX · since 2020
Hugh Wehby
Chief Executive Officer, Managing Director · since 2024
Amanda Baxter
Chief Commercial Officer · since 2025
Group Executive - People, Culture and Sustainability · since 2025
Vincent Portal-Barrault
Chief Financial Officer · since 2025
Daniel Krutik
Joint Company Secretary · since 2025
Paul Lynch
Joint Company Secretary · since 2021
Ken Daley
Non-Executive Director · since 2023
Danny Elia
Non-Executive Director of ATLAX · since 2024
Non-Executive Independent Director of ATLAX · since 2018
Non-Executive Independent Director of ATLIX · since 2019
Non-Executive Independent Director · since 2023
Andrew Cook
Non-Executive Independent Director of ATLIX · since 2020
Laura Hendricks
Non-Executive Independent Director · since 2023
Jean-Georges Malcor
Non-Executive Independent Director of ATLAX · since 2018
John Wigglesworth
Non-Executive Independent Director of ATLAX · since 2023
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||